Preventing Hereditary Diseases: A Comprehensive Guide to Pre-implantation Genetic Testing (PGT)

For many hopeful parents, the journey to starting a family comes with the heavy burden of genetic history. The fear of passing down a debilitating hereditary condition can make the prospect of pregnancy anxiety-inducing. However, modern reproductive medicine offers a powerful solution: Pre-implantation Genetic Testing (PGT). By screening embryos before they are implanted in the uterus, PGT allows parents to make informed decisions and significantly reduce the risk of transmitting genetic disorders to their children.

What is Pre-implantation Genetic Testing (PGT)?

Pre-implantation Genetic Testing (PGT) is a sophisticated screening process used in conjunction with in-vitro fertilisation (IVF). Unlike prenatal tests performed during pregnancy—such as amniocentesis or chorionic villus sampling—PGT happens before pregnancy is established.

During an IVF cycle, eggs are retrieved and fertilised in a lab. Once the embryos reach the blastocyst stage (usually day 5 or 6), a few cells are carefully removed from the trophectoderm—the part of the embryo that eventually becomes the placenta. These cells are then analysed for specific genetic markers or chromosomal abnormalities. This process ensures that only embryos with the highest likelihood of a healthy pregnancy are selected for transfer.

Understanding the Three Types of PGT

Not all genetic testing is the same. Depending on the parents’ medical history and goals, doctors recommend one of three primary types of PGT.

1. PGT-A (Aneuploidy Screening)

PGT-A screens for the number of chromosomes in an embryo. A healthy embryo typically has 46 chromosomes. If an embryo has too many or too few (aneuploidy), it often leads to implantation failure or miscarriage. PGT-A is commonly used to detect conditions like Down syndrome (Trisomy 21) and is frequently recommended for women of advanced maternal age, as the risk of chromosomal errors increases over time. You can learn more about chromosomal abnormalities via the National Center for Biotechnology Information (NCBI).

2. PGT-M (Monogenic/Single-Gene Disorders)

PGT-M is a targeted test used when parents are known carriers of a specific genetic mutation. This is the primary tool for preventing the transmission of single-gene disorders such as Cystic Fibrosis, Sickle Cell Anemia, or Huntington’s Disease. By creating a “genetic probe” tailored to the family’s specific mutation, clinicians can identify which embryos inherited the disease-causing gene and which did not.

3. PGT-SR (Structural Rearrangements)

Some individuals carry balanced translocations or inversions—where pieces of chromosomes are swapped or flipped. While the parent is healthy, these rearrangements can lead to embryos with unbalanced genetic material, which often results in recurrent pregnancy loss. PGT-SR identifies embryos that have a balanced set of chromosomes, increasing the chances of a viable pregnancy.

How the PGT Process Works

Integrating PGT into an IVF journey involves several precise steps:

• Ovarian Stimulation and Egg Retrieval: The patient takes medications to produce multiple eggs, which are then surgically retrieved.
• Fertilisation: Eggs are fertilised with sperm in the lab, often using Intracytoplasmic Sperm Injection (ICSI) to prevent contamination of the sample during later biopsy.
• Embryo Culture: Embryos grow for 5–6 days until they reach the blastocyst stage.
• The Biopsy: A skilled embryologist removes a tiny sample of cells from the outer layer of the blastocyst.
• Genetic Analysis: The cells are sent to a genetics lab for sequencing. While the analysis occurs, the embryos are frozen (cryopreserved).
• Frozen Embryo Transfer (FET): Once the results are back, the physician transfers an unaffected or euploid (chromosomally normal) embryo into the uterus.

Who Should Consider PGT?

While PGT is an option for many, it is particularly beneficial for specific groups. According to guidelines from the American Society for Reproductive Medicine (ASRM), the following patients should strongly consider genetic testing:

• Known Carriers: Couples who know they carry a mutation for a severe hereditary disease.
• Recurrent Pregnancy Loss: Women who have experienced multiple miscarriages, which may indicate chromosomal issues.
• Advanced Maternal Age: Women over 35, who have a higher statistical likelihood of aneuploidy in their oocytes.
• Previous Affected Child: Parents who have already had a child with a genetic disorder.

Frequently Asked Questions

Does PGT guarantee a healthy baby?

No test can provide a 100% guarantee. While PGT significantly reduces the risk of genetic disorders and miscarriages, it cannot screen for every possible mutation or developmental issue. Prenatal screening during pregnancy is still recommended.

Is PGT safe for the embryo?

Research indicates that the biopsy process is safe. Because the cells are taken from the trophectoderm (the future placenta) and not the inner cell mass (the future fetus), the risk of harming the embryo’s development is extremely low.

Is PGT expensive?

PGT adds a significant cost to an already expensive IVF cycle. However, many patients find it cost-effective in the long run by avoiding the emotional and financial toll of failed transfers and miscarriages.

The Future of Genetic Screening

The field of reproductive genetics is evolving rapidly. We are moving toward more comprehensive genomic sequencing that may one day identify polygenic risks—the combined effect of multiple genes—for conditions like heart disease or diabetes. While the current focus remains on preventing severe monogenic diseases, the goal is to provide parents with the most accurate biological roadmap possible to ensure the health of the next generation.